- Five research teams selected to receive funding for preclinical and
clinical research projects in Parkinson's disease-related cognitive
deficits and mood disorders
ROCKLAND, Mass., Oct. 14 /PRNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research (MJFF) awarded a total of $2 million to five research teams to speed development of effective therapies for the under-addressed cognitive and mood-related symptoms of Parkinson's disease (PD). The award was made possible by leadership funding from EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany.
The research grants will support preclinical and clinical projects under MJFF's Cognitive Deficits and Mood Disorders in Parkinson's Disease initiative. Patients often report these symptoms, which range from problems with executive function (the ability to formulate, sequence, and execute plans) to dementia; depression, apathy and anxiety; and behavioral issues including problems with impulse control, to be among the most difficult aspects of living with PD.
"Clinicians and patients alike report how disabling the cognitive and mood effects of PD can be, yet these symptoms are systematically under-researched and are poorly understood," said Katie Hood, CEO of The Michael J. Fox Foundation. "We are thrilled to have found a like-minded partner in EMD Serono so that we can push this work forward."
Elmar Schnee, Merck's Executive Board Member responsible for Pharmaceuticals, said: "We recognize the critical need for new therapies to alleviate PD-related cognitive dysfunction. We are pleased to stand side by side with The Michael J. Fox Foundation in prioritizing and supporting research with potential to help speed development of effective treatments that will allow every patient to live a fuller and more satisfying life."
The development of treatments for cognitive and mood symptoms of PD has
been hindered by a lack of preclinical mod
|SOURCE EMD Serono, Inc.|
Copyright©2008 PR Newswire.
All rights reserved